Department of Urology, The Fifth People's Hospital of Shanghai, Fudan University, Shanghai 200240, China.
Department of Urology, The Fifth People's Hospital of Shanghai, Fudan University, Shanghai 200240, China.
Am J Med Sci. 2022 Aug;364(2):220-228. doi: 10.1016/j.amjms.2022.03.001. Epub 2022 Mar 11.
Delta-like canonical notch ligand 4 (DLL4) is considered a potential prognostic gene for renal cell carcinoma (RCC). We assessed the molecular mechanisms and novel biomarkers associated with DLL4 during RCC development.
Four gene expression profiles were downloaded from the GEO database. Differentially expressed genes (DEGs) were identified between RCC and normal renal samples, including common DEGs (co-DEGs). Thereafter, RCC-associated gene exploration was performed and a PPI network was constructed to identify the core genes. Survival analysis of core genes in the high expression group (H group) and low expression group (L group) was also performed. The key genes related to the core genes were investigated, and the miRNA-target genes and TFs-target genes were analyzed. Finally, the expression levels of VEGFA, FLT1, EGLN3, and DLL4 in RCC and paracancerous tissues were determined.
A total of 11,867 DEGs and 622 co-DEGs were identified in this study, and 67 RCC-associated genes that were mainly enriched in signal transduction and angiogenesis function were further explored. VEGFA was identified as the core gene. Further, 30 DEGs and 9 DE-miRNAs were identified between the H and L groups. VEGFA was positively correlated with 19 genes, including EGLN3, FLT1, and DLL4. A total of 18 miRNA-target interactions, including miR-134-5p-DLL4, were obtained. VEGFA, FLT1, EGLN3, and DLL4 were significantly expressed in RCC tissues compared with paracancerous tissues.
DLL4 may contribute to the development of RCC by participating in signal transduction and angiogenesis. VEGFA, FLT1, EGLN3, DLL4, and miR-134-5p may be novel biomarkers for RCC.
Delta-like 经典 Notch 配体 4(DLL4)被认为是肾细胞癌(RCC)的潜在预后基因。我们评估了 DLL4 在 RCC 发展过程中相关的分子机制和新型生物标志物。
从 GEO 数据库中下载了四个基因表达谱。在 RCC 和正常肾样本之间确定了差异表达基因(DEGs),包括共同差异表达基因(co-DEGs)。然后,进行了与 RCC 相关的基因探索,并构建了 PPI 网络以确定核心基因。还对核心基因高表达组(H 组)和低表达组(L 组)进行了生存分析。研究了与核心基因相关的关键基因,并分析了 miRNA-靶基因和 TFs-靶基因。最后,测定了 RCC 和癌旁组织中 VEGFA、FLT1、EGLN3 和 DLL4 的表达水平。
本研究共鉴定出 11867 个 DEGs 和 622 个 co-DEGs,并进一步探索了主要富集在信号转导和血管生成功能中的 67 个与 RCC 相关的基因。VEGFA 被鉴定为核心基因。此外,在 H 组和 L 组之间还鉴定出 30 个 DEGs 和 9 个 DE-miRNAs。VEGFA 与包括 EGLN3、FLT1 和 DLL4 在内的 19 个基因呈正相关。共获得 18 个 miRNA-靶相互作用,包括 miR-134-5p-DLL4。VEGFA、FLT1、EGLN3 和 DLL4 在 RCC 组织中的表达明显高于癌旁组织。
DLL4 可能通过参与信号转导和血管生成而促进 RCC 的发展。VEGFA、FLT1、EGLN3、DLL4 和 miR-134-5p 可能是 RCC 的新型生物标志物。